Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is a first in human, phase 1, multicenter, open-label study to determine the safety and
tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory
MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or
is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to
evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the
study, from screening of the first participant to the end of the study, is expected to be
approximately 60 months.